Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akaal Pharma, a clinical-stage biopharmaceutical company today announced the approval to initiate a randomized, double-blind, placebo-controlled Phase-2 clinical trial of its topical drug candidate AKP-11.
Subscribe to our email newsletter
AKP-11 is a novel First-in-Class topical Sphingosine 1-Phosphate receptor-1 (S1P1) modulator for the treatment of mild-to-moderate plaque psoriasis in patients. Patients will be treated daily for six weeks with the topical drug AKP-11.
"We are pleased with the results of our recently completed Phase 1 clinical trial in which our drug candidate AKP-11 has shown an excellent safety, tolerability and efficacy for treating psoriasis. We look forward to initiating our Phase 2 clinical trial for demonstrating clinical efficacy, safety and tolerability in patients with mild-to-moderate psoriasis.
"This milestone advances us one step closer to our goal of providing new safer and effective treatments to physicians to help patients with psoriasis and other dermatological conditions," said Dale Dhanoa, Ph.D., CEO of Akaal Pharma.
AKP-11 is a novel, potent and highly selective sphingosine 1-phosphate receptor-1 (S1P1) modulator undergoing clinical development for treating psoriasis, atopic dermatitis and other skin diseases.
AKP-11 was found to be safe, well tolerated and demonstrated significant efficacy in our recently completed Phase 1 clinical trial and our intensive non-clinical drug discovery and development.